106 related articles for article (PubMed ID: 8800734)
41. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching.
Smith JD; Rose ML; Pomerance A; Burke M; Yacoub MH
Lancet; 1995 Nov; 346(8986):1318-22. PubMed ID: 7475769
[TBL] [Abstract][Full Text] [Related]
42. Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients.
Arizón JM; Anguita M; Vallés F; Montero A; Sancho M; López-Rubio F; Latre JM; Calleja F; Casares J; Román M
J Heart Lung Transplant; 1993; 12(3):445-8; discussion 448-9. PubMed ID: 8329416
[TBL] [Abstract][Full Text] [Related]
43. Vascular endothelial cell HLA-DR antigen and myocyte necrosis in human allograft rejection.
Rabin BS; Griffith BP; Hardesty RL
J Heart Transplant; 1985 May; 4(3):293-5. PubMed ID: 3916499
[TBL] [Abstract][Full Text] [Related]
44. Influence of corticosteroid-free maintenance immunosuppression on allograft coronary artery disease after cardiac transplantation.
Ratkovec RM; Wray RB; Renlund DG; O'Connell JB; Bristow MR; Gay WA; Karwande SV; Doty DB; Millar RC; Menlove RL
J Thorac Cardiovasc Surg; 1990 Jul; 100(1):6-12. PubMed ID: 2366566
[TBL] [Abstract][Full Text] [Related]
45. Remote versus early corticosteroid wean outcomes in heart transplant recipients in the contemporary era.
Salgado BC; Fida N; Krisl J; Berens PM; Graviss EA; Nguyen DT; Hussain I; Kim JH; Suarez E; Trachtenberg B; Torre-Amione G; Bhimaraj A; Guha A
Clin Transplant; 2021 Aug; 35(8):e14382. PubMed ID: 34101911
[TBL] [Abstract][Full Text] [Related]
46. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients.
Becker DM; Chamberlain B; Swank R; Hegewald MG; Girardet R; Baughman KL; Kwiterovich PO; Pearson TA; Ettinger WH; Renlund D
Am J Med; 1988 Nov; 85(5):632-8. PubMed ID: 3055976
[TBL] [Abstract][Full Text] [Related]
47. Weaning of immunosuppression in living donor liver transplant recipients.
Takatsuki M; Uemoto S; Inomata Y; Egawa H; Kiuchi T; Fujita S; Hayashi M; Kanematsu T; Tanaka K
Transplantation; 2001 Aug; 72(3):449-54. PubMed ID: 11502975
[TBL] [Abstract][Full Text] [Related]
48. Steroid-free maintenance immunosuppression after heart transplantation.
Oaks TE; Wannenberg T; Close SA; Tuttle LE; Kon ND
Ann Thorac Surg; 2001 Jul; 72(1):102-6. PubMed ID: 11465161
[TBL] [Abstract][Full Text] [Related]
49. Corticosteroid-free maintenance immunosuppression after heart transplantation: feasibility and beneficial effects.
Price GD; Olsen SL; Taylor DO; O'Connell JB; Bristow MR; Renlund DG
J Heart Lung Transplant; 1992; 11(2 Pt 2):403-14. PubMed ID: 1571338
[No Abstract] [Full Text] [Related]
50. HLA-DR mismatch and histologically evaluated rejection episodes in cardiac transplants can be correlated.
Pfeffer PF; Foerster A; Frøysaker T; Simonsen S; Thorsby E
Transplant Proc; 1988 Jun; 20(3):367-8. PubMed ID: 3289163
[No Abstract] [Full Text] [Related]
51. Corticosteroid wean after heart transplantation-Is there a risk for antibody formation?
Elboudwarej O; Phan D; Patel JK; Liou F; Aintablian T; Osborne A; Yu Z; Reinsmoen N; Kobashigawa JA
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28135788
[TBL] [Abstract][Full Text] [Related]
52. HLA compatibility and graft survival after heart transplantation.
Vereerstraeten P; Abramowicz D; Andrien M
N Engl J Med; 1994 Aug; 331(6):404; author reply 404-5. PubMed ID: 8028632
[No Abstract] [Full Text] [Related]
53. [Weaning of immunosuppression in living-related liver transplantation].
Inomata Y; Takatsuki M; Uemoto S; Tanaka K
Nihon Rinsho Meneki Gakkai Kaishi; 1999 Dec; 22(6):431-5. PubMed ID: 10726480
[TBL] [Abstract][Full Text] [Related]
54. [Heart transplantation].
Dubost C
Bull Acad Natl Med; 1970 Oct; 154(24):615-20. PubMed ID: 4283820
[No Abstract] [Full Text] [Related]
55. Steroid withdrawal after heart transplantation in adults.
Heegaard B; Nelson LM; Gustafsson F
Transpl Int; 2021 Dec; 34(12):2469-2482. PubMed ID: 34668614
[TBL] [Abstract][Full Text] [Related]
56. Persistence of donor-specific class II antigens in allografted human heart two years after transplantation.
Rose M; Navarette C; Yacoub M; Festenstein H
Hum Immunol; 1988 Nov; 23(3):179-90. PubMed ID: 3068219
[TBL] [Abstract][Full Text] [Related]
57. Corticosteroid withdrawal after renal transplantation in the cyclosporin era: timing, benefits and risks.
Hricik DE; Schulak JA
BioDrugs; 1997 Aug; 8(2):139-49. PubMed ID: 18020502
[TBL] [Abstract][Full Text] [Related]
58. Effect on Long-Term Mortality of HLA-DR Matching in Heart Transplantation.
Cacciatore F; Amarelli C; Sabia C; Mattucci I; Marra C; Romano G; Abete P; Maiello C; Napoli C
J Card Fail; 2019 May; 25(5):409-411. PubMed ID: 30682428
[No Abstract] [Full Text] [Related]
59. Corticosteroid Weaning in Stable Heart Transplant Patients: Guidance by Serum Cortisol Level.
Baran DA; Rosenfeld C; Zucker MJ
J Transplant; 2018; 2018():3740395. PubMed ID: 29670764
[TBL] [Abstract][Full Text] [Related]
60. [Urinary excretion of epinephrine in patients on short-term and long-term corticosteroid therapy].
Jesić S; Nesović M; Stepanović S; Mićić J
Srp Arh Celok Lek; 1985 Jan; 113(1):29-40. PubMed ID: 4049119
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
